137 related articles for article (PubMed ID: 25434618)
21. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
[TBL] [Abstract][Full Text] [Related]
22. External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: time trends, outcome, and risk stratification.
Yoshioka Y; Suzuki O; Kobayashi K; Teshima T; Yamada Y; Kotsuma T; Koizumi M; Kagawa K; Chatani M; Shimamoto S; Tanaka E; Yamazaki H; Inoue T
Strahlenther Onkol; 2009 Jul; 185(7):446-52. PubMed ID: 19714306
[TBL] [Abstract][Full Text] [Related]
23. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.
Leyh-Bannurah SR; Dell'Oglio P; Tian Z; Schiffmann J; Shariat SF; Suardi N; Francesco M; Alberto B; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
World J Urol; 2017 Feb; 35(2):189-197. PubMed ID: 27289238
[TBL] [Abstract][Full Text] [Related]
24. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
25. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
26. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).
Kupelian PA; Buchsbaum JC; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):621-5. PubMed ID: 11395228
[TBL] [Abstract][Full Text] [Related]
27. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
[TBL] [Abstract][Full Text] [Related]
28. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.
Hervás A; Gómez-Caamaño A; Casaña M; Gómez-Iturriaga A; Pastor J; Jove J; Mengual JL; Gónzalez-San Segundo C; Muñoz J
Clin Transl Oncol; 2018 Feb; 20(2):193-200. PubMed ID: 28667448
[TBL] [Abstract][Full Text] [Related]
30. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
[TBL] [Abstract][Full Text] [Related]
31. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.
Bajaj S; Donnelly D; Call M; Johannet P; Moran U; Polsky D; Shapiro R; Berman R; Pavlick A; Weber J; Zhong J; Osman I
J Natl Cancer Inst; 2020 Sep; 112(9):921-928. PubMed ID: 31977051
[TBL] [Abstract][Full Text] [Related]
32. The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant.
Vigneault E; Mbodji K; Carignan D; Martin AG; Miksys N; Thomson RM; Aubin S; Varfalvy N; Beaulieu L
Brachytherapy; 2019; 18(6):787-792. PubMed ID: 31444133
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
34. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate.
Lyons JA; Kupelian PA; Mohan DS; Reddy CA; Klein EA
Urology; 2000 Jan; 55(1):85-90. PubMed ID: 10654900
[TBL] [Abstract][Full Text] [Related]
35. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
[TBL] [Abstract][Full Text] [Related]
37. Salvage radiation therapy after radical prostatectomy: survival analysis.
Galla A; Maggio A; Delmastro E; Garibaldi E; Gabriele P; Bresciani S; Di Dia A; Stasi M; Gabriele D
Minerva Urol Nefrol; 2019 Jun; 71(3):240-248. PubMed ID: 30037205
[TBL] [Abstract][Full Text] [Related]
38. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
39. Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases.
Badakhshi H; Graf R; Budach V; Wust P
Strahlenther Onkol; 2015 Apr; 191(4):303-9. PubMed ID: 25339309
[TBL] [Abstract][Full Text] [Related]
40. [Salvage cryotherapy of prostate cancer after failed external radiotherapy and brachytherapy: Morbidity and mid-term oncological results].
Gevorgyan A; Hétet JF; Robert M; Duchattelle-Dussaule V; Corno L; Boulay I; Baumert H
Prog Urol; 2018 Apr; 28(5):291-301. PubMed ID: 29551263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]